PDK1: At the crossroad of cancer signaling pathways.

Rational target therapy of cancer would benefit from the identification of new targets that can be easily inhibited by small molecules. An increasing amount of evidence hints at 3-phosphoinositide dependent protein kinase-1 (PDK1 or PDPK1) as an intriguing and underexplored target for cancer therapy. Several reports show that PDK1 expression is dysregulated in multiple cancer types. Furthermore PDK1 is implicated in signaling pathways frequently altered in cancer, such as PI3K/Akt, Ras/MAPK and Myc. PDK1 targeting has been proven to be effective in experimental models harboring alterations of these pathways. In this paper we review PDK1 main biochemical mechanisms, its alterations in cancer and interactions with relevant cancer pathways. A potential role of PDK1 in tumor microenvironment is also discussed.

[1]  D. Alessi,et al.  Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. , 2012, The Biochemical journal.

[2]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[3]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[4]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[5]  D. Alessi,et al.  Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. , 1996, The Biochemical journal.

[6]  F. Orso,et al.  3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. , 2012, Neoplasia.

[7]  A. Newton,et al.  Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1) , 1998, Current Biology.

[8]  Xianneng Li,et al.  Correlation of PDK1 expression with clinicopathologic features and prognosis of hepatocellular carcinoma , 2016, OncoTargets and therapy.

[9]  K. Brown,et al.  PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. , 2015, Cancer research.

[10]  Zhonglin Han,et al.  Deletion of PDK1 Causes Cardiac Sodium Current Reduction in Mice , 2015, PloS one.

[11]  Ricardo M Biondi,et al.  AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. , 2013, Biochimica et biophysica acta.

[12]  T. Hagemann,et al.  The tumor microenvironment at a glance , 2012, Journal of Cell Science.

[13]  P. LoRusso.  Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Maria Deak,et al.  The PIF‐binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB , 2001, The EMBO journal.

[15]  P. Cohen,et al.  The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells , 2000, Current Biology.

[16]  Anna Dittrich,et al.  Perspectives in PDK1 evolution , 2012, Plant signaling & behavior.

[17]  H. Kluger,et al.  Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten−/− melanoma , 2013, Oncogene.

[18]  M. Humbert,et al.  Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. , 2008, Vascular pharmacology.

[19]  P. Seshiah,et al.  Phosphoinositide-Dependent Kinase 1 and p21-Activated Protein Kinase Mediate Reactive Oxygen Species–Dependent Regulation of Platelet-Derived Growth Factor–Induced Smooth Muscle Cell Migration , 2004, Circulation research.

[20]  B. Schaffhausen,et al.  Essential role of PDK1 in regulating endothelial cell migration , 2007, The Journal of cell biology.

[21]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[22]  David K. Finlay,et al.  Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes , 2009, The Journal of experimental medicine.

[23]  P. Knoepfler.  Myc goes global: new tricks for an old oncogene. , 2007, Cancer research.

[24]  Zhuomei Lu,et al.  3-Phosphoinositide–Dependent Protein Kinase-1 Regulates Proliferation and Survival of Cancer Cells with an Activated Mitogen-Activated Protein Kinase Pathway , 2010, Molecular Cancer Research.

[25]  R. Rad,et al.  Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. , 2013, Cancer cell.

[26]  Jorma Isola,et al.  3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. , 2009, Cancer research.

[27]  Lei Han,et al.  Upregulation of PDK1 associates with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro , 2014, Medical Oncology.

[28]  M. Barbacid,et al.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.

[29]  A. Kantarcı,et al.  PDK1 Regulates Chemotaxis in Human Neutrophils , 2009, Journal of dental research.

[30]  Zhongzhou Yang,et al.  PDK1 Regulates Vascular Remodeling and Promotes Epithelial-Mesenchymal Transition in Cardiac Development , 2010, Molecular and Cellular Biology.

[31]  Qiang Yu,et al.  B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. , 2010, Cancer cell.

[32]  D. Alessi,et al.  The serine kinase phosphoinositide-dependent kinase 1 (PDK1) regulates T cell development , 2004, Nature Immunology.

[33]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[34]  Allison K. Doak,et al.  A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1 , 2014, Proceedings of the National Academy of Sciences.

[35]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[36]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[37]  S. Chandarlapaty,et al.  PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition , 2016, Cancer cell.

[38]  O. Dormond,et al.  PI3K and AKT: Unfaithful Partners in Cancer , 2015, International journal of molecular sciences.

[39]  Kui-Sheng Chen,et al.  Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[40]  Philip R. Cohen,et al.  Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. , 1998, Science.

[41]  R. Hills,et al.  The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts , 2014, Haematologica.

[42]  S. Gammeltoft,et al.  90-kDa Ribosomal S6 Kinase Is Phosphorylated and Activated by 3-Phosphoinositide-dependent Protein Kinase-1* , 1999, The Journal of Biological Chemistry.

[43]  A. Harris,et al.  Igf2 ligand dependency of Pten+/− developmental and tumour phenotypes in the mouse , 2011, Oncogene.

[44]  A. Puliafito,et al.  PDK1-mediated activation of MRCKα regulates directional cell migration and lamellipodia retraction , 2014, The Journal of cell biology.

[45]  T. Hunter,et al.  Protein kinase signaling networks in cancer. , 2011, Current opinion in genetics & development.

[46]  Ximing J. Yang,et al.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.

[47]  N. C. Price,et al.  Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. , 2003, The Biochemical journal.

[48]  S. Ha,et al.  AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation , 2015, The Journal of cell biology.

[49]  M. Andjelkovic,et al.  Phosphorylation and activation of p70s6k by PDK1. , 1998, Science.

[50]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[51]  R. Glazer,et al.  Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. , 2002, Cancer research.

[52]  Ying Qi,et al.  Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization* , 2003, Journal of Biological Chemistry.

[53]  M. Troxell,et al.  Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. , 2011, Cancer research.

[54]  David K. Finlay,et al.  Phosphoinositide (3,4,5)-Triphosphate Binding to Phosphoinositide-Dependent Kinase 1 Regulates a Protein Kinase B/Akt Signaling Threshold That Dictates T-Cell Migration, Not Proliferation , 2009, Molecular and Cellular Biology.

[55]  D. Alessi,et al.  Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia , 2003, The EMBO journal.

[56]  Zhongzhou Yang,et al.  PDK1 plays a critical role in regulating cardiac function in mice and human. , 2010, Chinese medical journal.

[57]  M. Kasuga,et al.  The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-κB and activate T cells , 2009, Nature Immunology.

[58]  P. Li,et al.  Overexpression of 3-phosphoinositide-dependent protein kinase-1 is associated with prognosis of gastric carcinoma , 2016, Tumor Biology.

[59]  F. Liu,et al.  Fine Tuning PDK1 Activity by Phosphorylation at Ser163* , 2006, Journal of Biological Chemistry.

[60]  D. V. van Aalten,et al.  PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.

[61]  Frank McCormick,et al.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.

[62]  S. Ghosh,et al.  PDK1 Nucleates T Cell Receptor-Induced Signaling Complex for NF-κB Activation , 2005, Science.

[63]  K. Lerea,et al.  Threonine Phosphorylation of the β3 Integrin Cytoplasmic Tail, at a Site Recognized by PDK1 and Akt/PKB in Vitro, Regulates Shc Binding* , 2000, The Journal of Biological Chemistry.

[64]  A. J. Bain,et al.  Regulation of 3-Phosphoinositide–Dependent Protein Kinase 1 Activity by Homodimerization in Live Cells , 2010, Science Signaling.

[65]  M. Falasca,et al.  Emerging role of the KRAS-PDK1 axis in pancreatic cancer. , 2014, World journal of gastroenterology.

[66]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[67]  P. Cohen,et al.  Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. , 1999, The Biochemical journal.

[68]  M. Henriksson,et al.  Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation , 2009, Proceedings of the National Academy of Sciences.

[69]  R. Glazer,et al.  3-Phosphoinositide-dependent Protein Kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases , 2006, BMC Cancer.

[70]  P. Dent,et al.  Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. , 2005, Molecular cancer therapeutics.

[71]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[72]  M. Kulesz-Martin,et al.  Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling , 2015, Oncogene.

[73]  Maria Deak,et al.  Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C‐terminal residues of PKA , 2000, The EMBO journal.

[74]  M. Gleave,et al.  The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. , 2012, Translational oncology.

[75]  N. Saitou,et al.  The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.

[76]  Davalyn R. Powell,et al.  Neutrophils in the Tumor Microenvironment. , 2016, Trends in immunology.

[77]  K. Kunii,et al.  PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. , 2011, Cancer research.

[78]  F T Zenke,et al.  p21-activated Kinase (PAK1) Is Phosphorylated and Activated by 3-Phosphoinositide-dependent Kinase-1 (PDK1)* , 2000, The Journal of Biological Chemistry.

[79]  A. Casamayor,et al.  Characterisation of a plant 3‐phosphoinositide‐dependent protein kinase‐1 homologue which contains a pleckstrin homology domain , 1999, FEBS letters.

[80]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[81]  A. Prescott,et al.  Essential role of PDK1 in regulating cell size and development in mice , 2002, The EMBO journal.

[82]  E. Sahai,et al.  PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE , 2008, Nature Cell Biology.

[83]  A. Puliafito,et al.  PDK1 regulates focal adhesion disassembly by modulating endocytosis of &agr;v&bgr;3 integrin , 2015, Journal of Cell Science.

[84]  X. Wang,et al.  α-SMA-Cre-mediated excision of PDK1 reveals an essential role of PDK1 in regulating morphology of cardiomyocyte and tumor progression in tissue microenvironment. , 2015, Pathologie-biologie.

[85]  Nicholas H. Putnam,et al.  The amphioxus genome and the evolution of the chordate karyotype , 2008, Nature.

[86]  L. Primo,et al.  PDK1: A signaling hub for cell migration and tumor invasion. , 2015, Biochimica et biophysica acta.

[87]  S. Baker,et al.  Cell type specificity of PI3K signaling in Pdk1- and Pten-deficient brains. , 2009, Genes & development.

[88]  A. Prescott,et al.  Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates , 2004, The EMBO journal.

[89]  M. Lisanti,et al.  A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. , 2009, The American journal of pathology.

[90]  Qiang Yu,et al.  PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. , 2013, Cancer discovery.

[91]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[92]  D R Alessi,et al.  Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. , 1999, The Biochemical journal.

[93]  M. Taniwaki,et al.  Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. , 2014, Cancer research.

[94]  R. Parsons,et al.  Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice , 2005, Current Biology.

[95]  Yoshiyuki Kuchino,et al.  Regulation of c-Myc through Phosphorylation at Ser-62 and Ser-71 by c-Jun N-Terminal Kinase* , 1999, The Journal of Biological Chemistry.